Science

Clinical management

Spectacles
Contact Lenses
Orthokeratology
Pharmaceuticals
Visual Environment
Clinical Management
Myopia Progression
Mechanisms
Efficacy
Pathology

Clinical management

IMI 2021 Yearly Digest

The IMI 2021 Yearly Digest summarized recent updates and progress in research of myopia, taking in all publications since the IMI Volume One reports published in early 2019. Each of the Volume One reports included an update – definitions, interventions, genetics, experimental models, clinical trial guidance, ethical considerations and clinical management. While further research is needed, the strengthening evidence base indicates eye care practitioners should embrace proactive myopia management.

IMI Report on Prevention of myopia and its progression

In myopic children, interventions to slow progression are warranted to prevent the development of high myopia and subsequent pathology and also to reduce the economic burden caused by uncorrected and pathologic myopia. This IMI Report describes the latest advice on preventing the development and progression of myopia – read the summary here.

IMI Report on Pathologic Myopia

This IMI Report takes a deep dive into pathological myopia, including its prevalence and defining characteristics. The role of optical coherence tomography (OCT) is discussed, as well as emerging treatment options. Read the summary here.

Can myopia calculators accurately predict children’s myopia progression?

This study investigated the accuracy of the Brien Holden Vision Institute (BHVI) myopia calculator in predicting myopia progression. The extent of myopia progression over 1-2 years in children corrected with single vision spectacles was accurately predicted by the BHVI myopia calculator in 32-38% of 7-13 year old Hong Kong children. Around one-third progressed more and one-third progressed less than the range predicted by the calculator.

What is the effect of uncorrecting, undercorrecting and overcorrecting myopia in children?

This systematic review of 9 studies confirms that under-correction of myopia does not slow progression; rather, at least half of the studies have shown the myopia progression is accelerated. There was no benefit found in overcorrection, and the evidence for un-correction was equivocal. Clinically, this advocates for the full correction of myopia.

Myopia Management in the netherlands: advice and outcomes from a new protocol

The Erasmus Medical Group in the Netherlands set out four steps in their myopia management protocol: providing visual environment advice, identifying high-risk myopes by axial length and treating them with atropine 0.5%, managing other myopes with optical treatments or lower-concentration atropine, and ceasing treatment in the late teens once axial length is stable. The described use of axial length percentile growth charts for diagnosis, choice of treatment, monitoring and cessation is a world-first.

Race as a predictor of myopia progression in paediatric patients

Myopia has multi-factorial causes with both nature and nurture contributing. In this research the authors used a retrospective cohort study to examine any differences in progression rate with different ethnicities and greater understand who may be at increased risk of myopic progression.

GSLS2020 Part 2 – The parents, the patients and your practice

Welcome to Part 2 of the news update of the 2020 Global Specialty Lens Symposium, held in Las Vegas. Read on for updates on the risk-to-benefit comparison of myopia control, how to talk myopia successfully with parents and how to integrate myopia control into your practice.